eliquis apixaban logo eliquis apixaban logo eliquis apixaban logo

This information is intended for healthcare professionals based in the UK.

If you are not a healthcare professional in the UK, please click here.

For Prescribing and Adverse Event reporting information, click here.

desk-img mob-img

Adverse reactions

The safety of ELIQUIS (apixaban) has been investigated in 7 Phase III clinical studies including more than 21,000 patients:1

More than
11,000
patients in
NVAF studies1

More than
5,000
patients in
VTEp studies1

More than
4,000
patients in the
VTE treatment (VTEt) studies1

Haemorrhage, contusion, epistaxis, and haematoma (see table below for adverse reaction profile and frequencies by indication).

Diagnosemethoden

ELIQUIS is approved for a broad range of indications1

The approved indications for ELIQUIS are based on a robust clinical trial programme1

Access further resources, including videos, patient materials and downloadable supporting materials


ELIQUIS (apixaban) SmPC

Please click here to access the ELIQUIS SmPC.

ELIQUIS (apixaban) Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflet.

AMPLIFY = Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line   
AMPLIFY-EXT = Apixaban after the Initial Management of Pulmonary Embolism and Deep Vein Thrombosis with First-Line Therapy–Extended Treatment   
ARISTOTLE = Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation   
AVERROES = Apixaban Versus Acetylsalicylic Acid [ASPIRIN] to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment   
DVT = Deep Vein Thrombosis   
ISTH = International Society on Thrombosis and Haemostasis   
GI = Gastrointestinal   
NVAF = Non-Valvular Atrial Fibrillation   
PE = Pulmonary Embolism   
VTE = Venous Thromboembolic Events

Reference

  1. ELIQUIS® (apixaban) Summary of Product Characteristics.